SUN-174 Severe Insulin Resistance and Diabetic Ketoacidosis after Brentuximab Vendotin and Cyclosporin Treatment

Introduction: Brentuximab Vendotin(BV) is antibody-drug conjugate that selectively delivers cytotoxic agent, monomethyl auristatin E, targeting cells expressing surface CD30, treatment approved for refractory Hodgkin’s lymphoma. Previous research suggested MDR1 inhibition (cyclosporine) can overcome...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Lee, Hyunju, Reijonen, Helena, King, Victoria, Salehian, Behrouz
Format: Artigo
Language:Inglês
Published: Endocrine Society 2019
Subjects:
Diabetes Mellitus and Glucose Metabolism
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552905/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-174
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items